<DOC>
	<DOCNO>NCT00004581</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness 2 anti-HIV drug combination HIV-infected patient . Both combination include nevirapine ( NVP ) , 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) , least 1 protease inhibitor ( PI ) . One combination include new protease inhibitor , ABT-378 , combine capsule ritonavir ( RTV ) .</brief_summary>
	<brief_title>A Study Compare Two Anti-HIV Drug Combinations HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment</brief_title>
	<detailed_description>Patients receive 1 following : 1 . ABT-378/RTV plus NVP plus 2 NRTIs ; 2 . Investigator-selected PI ( ) plus NVP plus 2 NRTIs .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 12 year old . Are HIVpositive viral load ( level HIV blood ) 1,000 100,000 copies/ml . Are currently take antiHIV drug combination include 1 PI 2 NRTIs , change least 12 week . Are naive ( never take ) least 1 NRTI , zalcitabine abacavir . Agree abstinence use effective barrier method ( e.g. , condom ) birth control . Exclusion Criteria Patients eligible study : Have active illness . Have receive treatment active opportunistic ( AIDSrelated ) infection within 30 day study entry . Have ever receive nonnucleoside reverse transcriptase inhibitor ( NNRTI ) . Have receive investigational ( yet approve FDA ) drug within 30 day study entry . Have receive treatment PI current PI . Are receive chemotherapy cancer . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>ABT 378</keyword>
</DOC>